Alerta

METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER

Resumen de: US20260092932A1

0000 Disclosures herein are directed to methods and compositions for the detection of a panel of proteins as markers for ASD. Based on the results achieved from the methods disclosed herein, ASD can be diagnosed and suitable treatments for ASD may be designed and administered to the subject.

ANTI-APRIL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF

Resumen de: WO2026067804A1

Provided in the present invention is an anti-APRIL antibody or an antigen-binding fragment thereof. Further provided are a polynucleotide encoding the antibody, a vector and host cell for expressing the antibody, a pharmaceutical composition containing the antibody, a method for treating APRIL-associated diseases using the antibody, and the pharmaceutical use thereof.

USE OF DISCOIDIN DOMAIN RECEPTOR 2 IN DIAGNOSIS OF NEURODEGENERATIVE DISEASES, AND RELATED COMPUTER READABLE MEDIUM

Resumen de: US20260092920A1

The present invention discloses use of an agent for detecting the expression level of discoidin domain receptor 2 (DDR2) in the preparation of a kit for diagnosing a neurodegenerative disease in a subject, wherein the level of DDR2 in a sample from the subject being higher than the level of a control not having the disease indicates that the subject has the neurodegenerative disease. The present invention also discloses a kit and a method for diagnosing a neurodegenerative disease, and a computer-readable storage medium. The present invention can efficiently and accurately diagnose the neurodegenerative disease by detecting DDR2.

BRAIN-ON-A-CHIP DESIGNS AND LAYOUTS AND METHODS FOR USING SAME

Resumen de: AU2024356356A1

A BoC includes one or more chambers configured to house a population of neurons to be cultured, and one or more cellular-communication platforms placed between at least one pair of chambers from the one or more chambers. The cellular- communication platforms include one or more features/structures configured, shaped, sized, and arranged to promote axonal growth of the population of neurons in a preferred direction and impede axonal growth in directions opposite to the preferred direction, thereby providing control over at least one of, directionality, transmittance, and/or lateral spread between the populations of neurons being cultured. The cellular-communication platforms generate a neuronal circuit between the population of neurons in each pair of the chambers.

METHOD OF USING A FLAVOUR AND AROMA GENERATION SYSTEM

Resumen de: US20260090759A1

0000 A method of measuring an individual's taste and/or smell perception comprises a system to deliver to a user pluralities of artificial flavour sensations to be compared each comprising a plurality of taste and smell components selected from the group comprising sweetness, sourness, saltiness, bitterness, umami, astringency, capsaicin, oiliness, and aroma components. Each plurality contains at least one base flavour and one flavour to be compared against the base flavour. Delivery for the flavours can be through cups, vials, or other vessels. The system may identify a deviation of individual's flavour perception from that of a normal population's flavour perception distribution.

SYSTEMS AND METHODS FOR BIOMARKER DETECTION

Resumen de: US20260092302A1

0000 Provided herein are systems, compositions, and methods for detecting analytes (e.g., proteins, nucleic acid molecules, biomolecules, peptides, antibodies, biomarkers). In an aspect, a method for analyte detection, comprising: (a) providing: (i) a first probe coupled to a surface of a substrate, and (ii) said analyte; (b) binding said first probe coupled to said surface of said substrate and a second probe to said analyte, to generate a complex; (c) using said first probe and said second probe of said complex to generate a reaction product; and (d) detecting said analyte using said reaction product.

METHOD FOR DETECTING TEST SUBSTANCE DERIVED FROM AMYLOID-β PRECURSOR PROTEIN, METHOD FOR REDUCING INFLUENCE OF CHELATING AGENT, BUFFER REAGENT, AND REAGENT KIT

Resumen de: WO2026071006A1

The present invention is such that a test substance derived from an amyloid-β precursor protein in a blood sample, a substance that binds to the test substance, and a buffer solution are brought into contact for 6 minutes or less. The buffer solution contains a buffering agent where the concentration at the time of contact is 25 mM or more, and is such that the pH is 3.5 to 9.0. A signal derived from the binding between the test substance and the substance binding to the test substance is measured.

DIAGNOSIS, PROGNOSIS AND THERAPY OF NEUROINFLAMMATORY AUTOIMMUNE DISEASES USING CELLULAR AND SOLUBLE BLOOD PARAMETERS

Resumen de: US20260092917A1

The present invention relates to a method for determining distinguishing parameters of a neuro-inflammatory disease, said method comprising (a) obtaining parameters from a group of samples, wherein said group of samples comprises at least (i) a first subgroup of samples, and (ii) a second subgroup of samples, and (b) determining distinguishing parameters of the obtained parameters in step (a) at least between said first subgroup of samples and said second subgroup of samples by conducting analytical determination. Further, the present invention relates to a set of distinguishing parameters as well as distinct uses of such sets. Additionally, the present invention relates to a method for determining a subtype of a neuro-inflammatory autoimmune disease in a subject.

PROTEINACEOUS MOLECULES AND USES THEREFOR

Resumen de: WO2026064840A1

This disclosure relates generally to proteinaceous molecules that bind to pathological transactive response DNA binding protein of 43 kDa (TDP-43), such as a TDP-43 aggregate, and their use for determining the presence of pathological TDP-43 in the brain of a subject. More particularly, this disclosure relates to proteinaceous molecules and conjugates comprising such proteinaceous molecules and a labelling moiety that bind to pathological TDP-43 and their use for determining if a subject has a neurodegenerative disease associated with TDP-43 pathology and, optionally, further treating said subject for the neurodegenerative disease.

DETECTION OF AUTOANTIBODIES AGAINST NR1

Resumen de: WO2026073156A1

The disclosure provides systems and methods for detecting anti-NMDAR autoantibody based on the strong affinity of anti-NMDAR autoantibodies to a plurality of non-randomized anti-NR1 coupled to a solid support. The disclosure further provides therapeutic methods for an anti-NMDAR pathology by a therapeutic anti-NMDAR antibody, ART5803. The disclosure further provides methods and systems for screening and predicting the potential responsiveness to ART5803 treatment.

Bcl2 Family in Dysfunctional Neurons Is Critical to the Evolution, Diagnosis and Treatment of Neurodegenerative Diseases Including but Not Limited to Corticobasal Degeneration, Chronic Traumatic Encephalopathy, Amyotrophic Lateral Sclerosis (Als), Alzheimer's Disease, Parkinson's Disease, Down's Syndrome Dementia, and Lewy Body Dementia

Resumen de: US20260092931A1

Diagnostic and therapeutic methods for neurodegenerative diseases. Are provided involving assaying abnormal proteins (hyperphosphorylated tau, α-synuclein, TDP-43) associated with neuronal turnover inhibition or promotion in patient samples. Abnormal protein expression and apoptotic activity are detected, aiding disease progression assessment. Therapeutically, a method is provided for treating neurodegenerative diseases, administering compounds promoting neuronal turnover or modulating proteins involved in the process. The invention extends to identifying suitable drugs, employing neuronal turnover induction, miRNA modulation, and protein activity inhibition or enhancement. The claims also encompass various species, tissues, and cultured cells. Furthermore, the invention is applicable to diverse neurodegenerative diseases with abnormal protein accumulation, presenting novel diagnostic and treatment approaches.

NERVE CELL ANALYSIS METHOD, KIT, AND SCREENING METHOD FOR PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE

Resumen de: WO2026071242A1

The present invention addresses the problem of providing: a nerve cell analysis method with which the localized amount of TDP-43 in nerve cells can be analyzed without labeling TDP-43 with a fluorescent tag or the like and without carrying out gene transfer; a kit for carrying out the nerve cell analysis method; and a screening method for a prophylactic and/or therapeutic agent for a neurodegenerative disease. The present invention provides a nerve cell analysis method involving: a staining step for immunofluorescent staining of nerve cells using an anti-TDP-43 antibody and an antibody that recognizes a stress granule marker; a cell region identification step for identifying the cytoplasm and nuclei of the nerve cells; and an analysis step for analyzing a TDP-43-derived fluorescence signal and a stress granule marker-derived fluorescence signal in the cytoplasm, and analyzing the localized amount of TDP-43 in the nerve cells on the basis of the presence or absence of colocalization of a granular TDP-43 signal and a granular stress granule marker signal in the cytoplasm.

METHOD FOR PREPARING BIOCHIP AND BIOCHIP PREPARED THEREFROM

Resumen de: WO2026072743A1

The present disclosure provides a method for preparing a biochip. The method includes coating a chip with a first solution of biotin to form a biotin-coated chip, wherein the biotin in the first solution is at a first concentration; subjecting the biotin-coated chip to a second solution of neutravidin to form a neutravidin/biotin-coated chip, wherein the neutravidin in the second solution is at a second concentration; and subjecting the neutravidin/biotin-coated chip to a third solution of a biotinylated probe to form the biochip, wherein a first molar ratio of the first concentration to the second concentration is 1 : 1, 1 :0.25, or 1 :2.

BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE

Resumen de: US20260091025A1

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.

ANTIBODY WHICH BINDS TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN

Resumen de: US20260092110A1

0000 The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.

BIOLOGICAL STATUS CLASSIFICATION

Resumen de: US20260092926A1

0000 There is provided a method of classifying a biological status of an individual. The method comprising: obtaining a biological sample from a patient; obtaining health-related information from the patient, said information including patient gender; analysing the sample to identify a quantity of each of 2 or more endogenous analytes in the sample; comparing the analyte quantities to reference data from healthy individuals to classify the patient as healthy, pre-diseased, at risk of disease or diseased for at least one health-related condition. The reference data includes data derived from a group of biological samples of individuals having the same gender as the patient and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process as used to analyse the patient sample, the process being monitored to maintain a predetermined level of consistency.

DIAGNOSIS AND MONITORING OF NEURODEGENERATIVE DISEASES

Resumen de: US20260094269A1

0000 Disclosed is a method for diagnosing a neurodegenerative disease in a subject. The method comprises obtaining from the subject a sample comprising at least one live blood cell, and optionally isolating at least one live blood cell from the sample. The method further comprises generating one or more multispectral or hyperspectral images of the at least one cell, and analysing spectral characteristics of autofluorescence from the at least one cell. Also disclosed is a system configured to aid in the detection or diagnosis of a neurodegenerative disease. Also disclosed is a method for selecting a subject for treatment for a neurodegenerative disease. Also disclosed is a method for monitoring the response of a subject to a therapeutic treatment for a neurodegenerative disease. Also disclosed is a protocol for monitoring the efficacy of a therapeutic treatment for a neurodegenerative disease.

OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT

Resumen de: AU2026201900A1

The present disclosure provides genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy. Also described is use of the polymorphisms to personalize treatment for subjects in need of Sigma-1 receptor therapy such as treatment of neurodevelopmental and neurodegenerative diseases and conditions. ar a r

CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR ALZHEIMER'S DISEASE DIAGNOSIS

Resumen de: US20260092326A1

Biomarkers and methods for identifying, verifying and confirming circulating serum-based microRNAs. The microRNAs (PARKmiRs) can be used to differentiate patient's suffering from Alzheimer's disease (AD) from non-AD patients.

WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND MIDREGIONAL-PROADRENOMEDULLIN

Resumen de: EP4718076A2

The present invention is in the field of clinical diagnostics. Particularly, the present invention relates to the assessment of severity of a subject being suspected of an infection or having an infection, who may have physiological signs or increased risk factors for infection, in particular from an infectious disease by determination of the levels of Procalcitonin (hereinafter: PCT) (SEQ ID No: 1 and/ or proadrenomedullin (hereinafter: proADM)) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM) (SEQ ID No: 2), in a sample of a patient and the invention is related to a workflow hereto. Moreover, the invention refers to the assessment related to an infection like ruling out/in a patient and stratification, risk assessment, in particular to avoid rehospitalisation and hospital and post-discharge mortality.

SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS

Resumen de: WO2020028348A1

Provided herein is the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid- like aggregates, e.g., Alzheimer's disease.

METHOD OF DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE

Resumen de: MX2025014011A

Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.

P-TAU免疫测定

Resumen de: WO2025018933A1

The present embodiments relate to an immunoassay kit capable of measuring p-tau205 in a sample and to methods involving the use of such an immunoassay kit. The present embodiment also relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to p-tau205 and that can be used in such an immunoassay kit.

一种双功能化修饰磁珠及脑脊液中外泌体的提取方法

Resumen de: CN121762831A

0001 本发明属于生物医学领域，具体涉及一种双功能化修饰磁珠及脑脊液中外泌体的提取方法。针对现有磁珠捕获法在去除杂蛋白方面的不足，本发明首先提供了一种双功能化修饰的磁珠，表面修饰CD63抗体和磺基甜菜碱型两性离子聚合物，基于CD63与外泌体的抗原抗体特异性结合实现外泌体的特异性捕获，同时减少对杂蛋白的吸附作用。本发明上述磁珠应用于脑脊液中外泌体的提取，有效克服了脑脊液样本量少，传统方法回收率不高的技术缺陷。

一种MXene/酶修饰的乙酰胆碱纳米微电极及其在单囊泡释放乙酰胆碱分析中的应用

Nº publicación: CN121762651A 31/03/2026

Solicitante:

南京医科大学

Resumen de: CN121762651A

本发明公开了一种MXene/酶修饰的乙酰胆碱纳米微电极及其在单囊泡释放乙酰胆碱分析中的应用，将本发明构建的MXene/酶修饰的乙酰胆碱纳米微电极用于单囊泡释放乙酰胆碱分析。该方法依次包含乙酰胆碱纳米微电极构建、乙酰胆碱人工囊泡的制备、小鼠原代胆碱能神经元的提取与培养、单囊泡乙酰胆碱释放检测。为监测单细胞水平的乙酰胆碱单囊泡释放情况提供了新思路、新方法，对研究究神经系统发育、理解神经系统疾病生理病理过程以及其治疗中的调控规律具有重要意义。